Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Builds on 80MW of C&I Solar Growth in Czechia with GO Optimized ESS for Residential1.10.2026 07:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company will showcase the Tigo GO Optimized Energy Storage Solution (ESS) at Smart Energy Forum (SEF) 2026 in Prague, building on strong adoption of Tigo technology across the Czech commercial and industrial (C&I) solar market. Since 2024, Czech installers have deployed Tigo products in approximately 80MW of C&I systems, providing a solid foundation for Tigo to expand its residential solar-plus-storage offering. Across residential, small commercial, and larger C&I applications, installers in Czechia have deployed approximately 276MW of Tigo systems since 2024. At the heart of the Tigo showcase will be the Tigo GO Optimized ESS, featuring the expanded storage capacity of the new GO Battery, plus e-mobility and heat-pump integration, with intelligent system management through the Tigo Energy Intelligence monitoring platform. Visitors can
Umios and Wah Kong Complete Strategic Pet Food Joint Venture in Southeast Asia; Japan Corporate Advisory Institute Advised on the Transaction1.10.2026 03:00:00 EEST | Press release
Umios Corporation (TOKYO Prime: 1333; formerly Maruha Nichiro) and Wah Kong Corporation have completed the establishment of a strategic joint venture centered on Pet World International Sdn. Bhd. (“PWI”), one of Malaysia’s leading pet food companies. Under the transaction, Umios invested approximately JPY 11.4 billion to acquire a 51% interest in PWI through a newly established holding company. PWI holds the No. 2 share of Malaysia’s pet food market — No. 1 among local companies (NielsenIQ) — and operates the country’s only BRC-certified pet food plant. The company has approximately 350 employees, sells through more than 10,000 physical stores and its own e-commerce channels, and posted consolidated sales of approximately JPY 12.4 billion in the year ended September 2025. The joint venture combines Umios’s strengths in wet pet food with PWI’s dry-food capabilities, creating comprehensive coverage across dogs and cats, wet and dry. The partnership is expected to integrate the parties’ s
INNIO Completes Acquisition of Enerflex APAC Aftermarket Operations1.10.2026 00:02:00 EEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced the completion of its acquisition of Enerflex Ltd.’s aftermarket business operations in Australia, Thailand, and Indonesia. The transaction strengthens INNIO’s presence in the Asia-Pacific (APAC) region and expands its ability to serve customers through enhanced local service capabilities and greater customer proximity. The acquired business operates principally across three countries and eight locations and brings extensive workshop and office facilities, a highly experienced workforce, and a strong installed base supported by long-term service agreements with major oil and gas companies in the region. Through the transaction, INNIO further strengthens its ability to deliver responsive, high-quality service and lifecycle support to customers throughout APAC. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Textron Aviation Builds Future Workforce With Kansas’ First Aviation Youth Apprenticeship Program.30.9.2026 21:55:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, is further bolstering the company’s efforts to build the next generation workforce as the first aviation company in Kansas to offer state-registered youth apprenticeships through the Kansas Office of Apprenticeships. The program expands career opportunities for high school students beginning at age 16 by providing paid, hands-on learning experiences that develop industry knowledge and career-ready skills while they complete their education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930818829/en/ Textron Aviation builds future workforce with Kansas’ first aviation youth apprenticeship program (Photo Credit: Textron Aviation). Textron Aviation is launching three state-registered youth apprenticeship programs to include: Airframe & Powerplant (A&P) in collaboration with WSU Tech in Wichita, Kansas Avionics in collaboration with WSU Tech in Wichita, Kansas Engine
Thales and Landis+Gyr Enable Smarter, Remotely Managed Connectivity for Smart Meter Fleets30.9.2026 21:00:00 EEST | Press release
As utilities modernize their infrastructure, smart meters are becoming an increasingly important part of the connected energy ecosystem. Landis+Gyr serves more than 2,000 utilities worldwide and has more than 180 million connected intelligent devices in the field. In North America alone, the installed base of smart electricity meters is expected to grow from 152.4 million in 2024 to 180.9 million by 2030, according to Berg Insight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930715193/en/ This is where the latest generation of Thales eSIM technology is supporting the increasing need for cellular IoT. Compliant with the GSMA's SGP.32 specification, it enables remotely managing connectivity on IoT devices, allowing network profiles to be provisioned, changed or managed over the air. By reducing reliance on physical SIM replacement and supporting interoperability across the IoT ecosystem, it provides a foundation for more
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom